Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × niraparib × Clear all

Phase

Phase EARLY_PHASE1 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 23 Prostatic Neoplasms 8 Breast Neoplasms 7 Fallopian Tube Neoplasms 6 Pancreatic Neoplasms 5 Neoplasm Metastasis 4 Endometrial Neoplasms 4 Neoplasms 3 Head and Neck Neoplasms 3 Glioblastoma 3 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Recurrence 2 Mesothelioma, Malignant 2 Mesothelioma 2 Melanoma 2 Lung Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Uveal Melanoma 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Triple Negative Breast Neoplasms 1 Thrombocytopenia 1 Stomach Neoplasms 1 Solid Tumor 1 Sarcoma 1

Interventions

Temozolomide 56 Bevacizumab 37 Radiotherapy 19 Magnetic Resonance Spectroscopy 18 Irinotecan 15 Specimen Handling 9 Carmustine 9 Carboplatin 9 olaparib 6 X-Rays 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Cyclophosphamide 6 Thalidomide 5 Nuclear Medicine Department, Hospital 5 Biopsy 5 trametinib 4 pembrolizumab 4 Radiation 4 Nivolumab 4 Lomustine 4 Everolimus 4 Cisplatin 4 Aminolevulinic Acid 4 sargramostim 3 poly ICLC 3 ivosidenib 3 fluorodopa F 18 3 erdafitinib 3 dabrafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05297864 2025-05-23

OU-SCC-PI-4G

University of Oklahoma

Phase 2 Terminated

15 enrolled 13 charts

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡